[1] Kristensen LS, Jakobsen T, Hager H, et al. The emerging roles of circRNAs in cancer and oncology[J]. Nat Rev Clin Oncol, 2022, 19(3): 188-206. DOI: 10.1038/s41571-021-00585-y.
[2] Long F, Lin Z, Li L, et al. Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer[J]. Mol Cancer, 2021, 20(1): 26. DOI: 10.1186/s12943-021-01318-6.
[3] Lee AS, Kranzusch PJ, Doudna JA, et al. eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation[J]. Nature, 2016, 536(7614): 96-99. DOI: 10.1038/nature18954.
[4] Liberman N, Gandin V, Svitkin YV, et al. DAP5 associates with eIF2beta and eIF4AI to promote Internal Ribosome Entry Site driven translation[J]. Nucleic Acids Res,2015,43(7):3764-3775. DOI: 10.1093/ nar/gkv205.
[5] Wang Y, Wu C, Du Y, et al. Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas[J]. Mol Cancer, 2022, 21(1): 13. DOI: 10.1186/s12943-021-01484-7.
[6] Ali MM, Li F, Zhang Z, et al. Rolling circle amplification: a versatile tool for chemical biology, materials science and medicine[J]. Chem Soc Rev, 2014, 43(10): 3324-3341. DOI: 10.1039/c3cs60439j.
[7] Warminski M, Kowalska J, Jemielity J. Solid-phase synthesis of RNA 5'-azides and their application for labeling, ligation, and cyclization via click chemistry[J]. Curr Protoc Nucleic Acid Chem, 2020, 82(1): e112. DOI: 10.1002/cpnc.112.
[8] Tang X, Guo M, Ding P, et al. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability[J]. Signal Transduct Target Ther, 2021, 6(1): 361. DOI: 10.1038/s41392-021-00746-6.
[9] Gao X, Xia X, Li F, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling[J]. Nat Cell Biol, 2021, 23(3): 278-291. DOI: 10.1038/s41556-021-00639-4.
[10]Lu Y, Li Z, Lin C, et al. Translation role of circRNAs in cancers[J]. J Clin Lab Anal, 2021, 35(7): e23866. DOI: 10.1002/jcla.23866.
[11]Kim D, Han S, Ji Y, et al. Multimeric RNAs for efficient RNA-based therapeutics and vaccines[J]. J Control Release, 2022, 345: 770-785. DOI: 10.1016/j.jconrel.2022.03.052.
[12]Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. DOI: 10.1038/s41576-019-0158-7.
[13]Li H, Peng K, Yang K, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies[J]. Theranostics, 2022, 12(14): 6422-6436. DOI: 10.7150/thno.77350.
[14]Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants[J]. Cell, 2022, 185(10): 1728e16-1744e16. DOI: 10.1016/j.cell.2022.03.044.
[15]Wang T, Liu Z, She Y, et al. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis[J]. Cancer Lett, 2021, 520: 321-331. DOI: 10.1016/j.canlet.2021.08.007.
[16]Suzuki H, Zuo Y, Wang J, et al. Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing[J]. Nucleic Acids Res, 2006, 34(8): e63. DOI: 10.1093/nar/gkl151.
[17]Xu Z, Li P, Fan L, et al. The potential role of circRNA in tumor immunity regulation and immunotherapy[J]. Front Immunol, 2018, 9: 9. DOI: 10.3389/fimmu.2018.00009.
[18]Liu X, Zhang Y, Zhou S, et al. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines[J]. J Control Release, 2022, 348: 84-94. DOI: 10.1016/j.jconrel.2022.05.043.
[19]Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production[J]. Genes Dev, 2014, 28(20): 2233-2247. DOI: 10.1101/gad.251926.114.
[20]Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs[J]. Cell, 2015, 160(6): 1125-1134. DOI: 10.1016/j.cell.2015.02.014.
[21]Qi Y, Han W, Chen D, et al. Engineering circular RNA regulators to specifically promote circular RNA production[J]. Theranostics, 2021, 11(15): 7322-7336. DOI: 10.7150/thno.56990.
[22]Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells[J]. Nat Commun, 2018, 9(1): 2629. DOI: 10.1038/s41467-018-05096-6.
[23]Wesselhoeft RA, Kowalski PS, Parker-Hale FC, et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo[J]. Mol Cell, 2019, 74(3): 508e4-520e4. DOI: 10.1016/j.molcel.2019.02.015.
[24]Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications[J]. Cell, 2022, 185(12): 2016-2034. DOI: 10.1016/j.cell.2022.04.021.
[25]Chen R, Wang SK, Belk JA, et al. Engineering circular RNA for enhanced protein production[J]. Nat Biotechnol, 2023, 41(2): 262-272. DOI: 10.1038/s41587-022-01393-0.
|
